Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: Final 5-year results of the GO-FORWARD trial

Journal of Rheumatology

Volumn 43, Issue 2, 2016, Pages 298-306

  Keystone, Edward C ^{a,b,c,d,e,f,g,h}   Genovese, Mark C ^{a,b,c,d,e,f,g,h}   Hall, Stephen ^{a,b,c,d,e,f,g,h}   Bae, Sang Cheol ^{a,b,c,d,e,f,g,h}   Han, Chenglong ^{a,b,c,d,e,f,g,h}   Gathany, Timothy A ^{a,b,c,d,e,f,g,h}   Xu, Stephen ^{a,b,c,d,e,f,g,h}   Zhou, Yiying ^{a,b,c,d,e,f,g,h}   Leu, Jocelyn H ^{a,b,c,d,e,f,g,h}   Hsia, Elizabeth C ^{a,b,c,d,e,f,g,h}  

^a UNIVERSITY OF TORONTO   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c Janssen Global Services LLC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g CABRINI INSTITUTE   (Australia)

^h Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

Biologics; Golimumab; Longterm; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; GOLIMUMAB; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ACUTE HEART INFARCTION; ACUTE LIVER FAILURE; ADULT; AGED; ARTICLE; ASPERGILLOMA; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CARDIOVASCULAR DISEASE; CELLULITIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEMALE; GASTROINTESTINAL CANDIDIASIS; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; LUNG CANCER; LUNG CARCINOMA; LUNG TUBERCULOSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIDDLE AGED; MILIARY TUBERCULOSIS; MUSCULOSKELETAL DISEASE; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UTERUS MYOMA; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE; TREATMENT OUTCOME;

EID: 84969375529     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150712     Document Type: Article

References (29)

1. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al; GO-FORWARD Study. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
2. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
3. Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol 2013;40:1097-103.
4. Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 2012;39:1185-91.
5. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
6. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-96.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. van Riel PL, van Gestel AM, Scott DL. EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen aan den Rijn: Van Zuiden Communications BV; 2000.
9. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
10. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
11. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004;22 Suppl 1:27-38.
12. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
13. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
14. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 2011;70:1631-40.
15. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007;7:35-41.
16. Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol 2011;38:855-62.
17. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005;32:1232-42.
18. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
19. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
20. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
21. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012;12:225-9.
22. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
23. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
24. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
25. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
26. Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante E, et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naïve patients with rheumatoid arthritis: 5-year results of the GO-BEFORE trial. Arthritis Care Res 2015 Oct 16 (E-pub ahead of print).
27. Smolen JS, Kay J, Doyle M, Landewé R, Matteson EL, Gaylis N, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor ? inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther 2015;17:14.
28. Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 2015;74:757-61.
29. Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 2014;73:1689-94.